Ezeprogind - AlzProtect
Alternative Names: AZP 2006Latest Information Update: 28 Feb 2025
At a glance
- Originator AlzProtect; INSERM; University of Lille 2
- Developer AlzProtect
- Class Antidementias; Antiparkinsonians; Neuroprotectants; Small molecules
- Mechanism of Action Progranulin protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Progressive supranuclear palsy
- Preclinical Parkinson's disease
- No development reported Alzheimer's disease
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in France (PO)
- 24 Sep 2024 AlzProtect completes a phase-II clinical trial in Progressive supranuclear palsy in France (PO) (NCT04008355)
- 18 Sep 2024 Efficacy data from a phase II trial in Progressive supranuclear palsy released by AlzProtect